Business Description
Moberg Pharma AB
ISIN : SE0020353928
Total Employee Number:
5Compare
Compare
Traded in other countries / regions
MOB.SwedenMBGPF.USAMB8.GermanyMOBs.UK IPO Date
2018-07-20Description
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 104.17 | |||||
Equity-to-Asset | 0.97 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 13.5 | |||||
Beneish M-Score | -2.32 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.9 | |||||
3-Year EPS without NRI Growth Rate | -38.6 | |||||
3-Year FCF Growth Rate | 31 | |||||
3-Year Book Growth Rate | -38.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 96.11 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.49 | |||||
9-Day RSI | 40.88 | |||||
14-Day RSI | 41.15 | |||||
3-1 Month Momentum % | 2.91 | |||||
6-1 Month Momentum % | 4.37 | |||||
12-1 Month Momentum % | 25.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.12 | |||||
Quick Ratio | 12.8 | |||||
Cash Ratio | 12.43 | |||||
Days Inventory | 327.16 | |||||
Days Sales Outstanding | 153.4 | |||||
Days Payable | 208.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -89.7 | |||||
Shareholder Yield % | 0.28 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.38 | |||||
Operating Margin % | -171.63 | |||||
Net Margin % | -176.32 | |||||
EBITDA Margin % | -139.07 | |||||
FCF Margin % | -305.16 | |||||
OCF Margin % | -83.48 | |||||
ROE % | -3.81 | |||||
ROA % | -3.71 | |||||
ROIC % | -5.47 | |||||
3-Year ROIIC % | -391.19 | |||||
ROC (Joel Greenblatt) % | -681.24 | |||||
ROCE % | -3.24 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 0.32 | |||||
PS Ratio | 30.99 | |||||
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 1.4 | |||||
EV-to-EBIT | -10.25 | |||||
EV-to-EBITDA | -11.07 | |||||
EV-to-Revenue | 15.4 | |||||
EV-to-FCF | -4.97 | |||||
Price-to-GF-Value | 0.75 | |||||
| Price-to-Net-Current-Asset-Value | 2.05 | |||||
| Price-to-Net-Cash | 2.16 | |||||
Earnings Yield (Greenblatt) % | -9.75 | |||||
FCF Yield % | -10.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Moberg Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.338 | ||
| EPS (TTM) (€) | -0.051 | ||
| Beta | -0.1282 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.71 | ||
| Volatility % | 36.83 | ||
| 14-Day RSI | 41.15 | ||
| 14-Day ATR (€) | 0.025816 | ||
| 20-Day SMA (€) | 0.84825 | ||
| 12-1 Month Momentum % | 25.2 | ||
| 52-Week Range (€) | 0.6575 - 1.096 | ||
| Shares Outstanding (Mil) | 47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Moberg Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Moberg Pharma AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 135 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 135 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 | In 44 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 44 days | ||
| General meeting for 2025 | 2026-05-21 13:00 | 0.94 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 0.94 (+0.00%) | ||
| Annual report for 2025 | 2026-04-17 | 0.90 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-17 | 0.82 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-11 | 0.91 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 0.77 (+0.00%) |
Show
Entries
Moberg Pharma AB Frequently Asked Questions
What is Moberg Pharma AB(FRA:MB8)'s stock price today?
The current price of FRA:MB8 is €0.80. The 52 week high of FRA:MB8 is €1.10 and 52 week low is €0.66.
When is next earnings date of Moberg Pharma AB(FRA:MB8)?
The next earnings date of Moberg Pharma AB(FRA:MB8) is 2026-08-13.
Does Moberg Pharma AB(FRA:MB8) pay dividends? If so, how much?
Moberg Pharma AB(FRA:MB8) does not pay dividend.
Press Release
Articles on Moberg Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers